163 related articles for article (PubMed ID: 1372812)
1. Pharmacological manipulation of tissue cyclic AMP by inhibitors. Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells.
Tani T; Sakurai K; Kimura Y; Ishikawa T; Hidaka H
Adv Second Messenger Phosphoprotein Res; 1992; 25():215-27. PubMed ID: 1372812
[No Abstract] [Full Text] [Related]
2. Phosphodiesterases in vascular endothelial cells.
Kishi Y; Ashikaga T; Numano F
Adv Second Messenger Phosphoprotein Res; 1992; 25():201-13. PubMed ID: 1372811
[No Abstract] [Full Text] [Related]
3. Therapeutic potential of isozyme-selective phosphodiesterase inhibitors in the treatment of asthma.
Torphy TJ; Livi GP; Balcarek JM; White JR; Chilton FH; Undem BJ
Adv Second Messenger Phosphoprotein Res; 1992; 25():289-305. PubMed ID: 1372813
[No Abstract] [Full Text] [Related]
4. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets.
Simpson AW; Reeves ML; Rink TJ
Biochem Pharmacol; 1988 Jun; 37(12):2315-20. PubMed ID: 2455518
[TBL] [Abstract][Full Text] [Related]
5. The effects of flavonoids on cyclic nucleotide phosphodiesterases.
Beretz A; Anton R; Cazenave JP
Prog Clin Biol Res; 1986; 213():281-96. PubMed ID: 3012580
[No Abstract] [Full Text] [Related]
6. Cyclic nucleotide phosphodiesterase inhibitors prevent aggregation of human platelets by raising cyclic AMP and reducing cytoplasmic free calcium mobilization.
Lanza F; Beretz A; Stierlé A; Corre G; Cazenave JP
Thromb Res; 1987 Mar; 45(5):477-84. PubMed ID: 3035738
[TBL] [Abstract][Full Text] [Related]
7. Identification of the phosphodiesterase regulated by muscarinic cholinergic receptors of 1321N1 human astrocytoma cells.
Tanner LI; Harden TK; Wells JN; Martin MW
Mol Pharmacol; 1986 May; 29(5):455-60. PubMed ID: 2422535
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cyclic nucleotide phosphodiesterase isoforms from rat heart and bovine aorta. Separation and inhibition by selective reference phosphodiesterase inhibitors.
Prigent AF; Fougier S; Nemoz G; Anker G; Pacheco H; Lugnier C; Lebec A; Stoclet JC
Biochem Pharmacol; 1988 Oct; 37(19):3671-81. PubMed ID: 2845994
[TBL] [Abstract][Full Text] [Related]
9. In vitro vascular relaxation by new inotropic agents: relationship to phosphodiesterase inhibition and cyclic nucleotides.
Kauffman RF; Schenck KW; Utterback BG; Crowe VG; Cohen ML
J Pharmacol Exp Ther; 1987 Sep; 242(3):864-72. PubMed ID: 2821228
[TBL] [Abstract][Full Text] [Related]
10. [Outer retinal rod segment cyclic nucleotide phosphodiesterase; protein inhibitor separation, bimodal effect of GTP].
Dumler IL; Furaev VV; Etingof RN
Dokl Akad Nauk SSSR; 1980; 253(6):1504-8. PubMed ID: 6253254
[No Abstract] [Full Text] [Related]
11. Properties of acidic saccharides produced by B16 melanoma cells treated with 1-methyl-3-isobutylxanthine.
Banks J; Kreider JW; Sato C; Davidson EA
Cancer Res; 1975 Sep; 35(9):2383-9. PubMed ID: 167957
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis.
Netherton SJ; Maurice DH
Mol Pharmacol; 2005 Jan; 67(1):263-72. PubMed ID: 15475573
[TBL] [Abstract][Full Text] [Related]
13. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors.
Beavo JA; Reifsnyder DH
Trends Pharmacol Sci; 1990 Apr; 11(4):150-5. PubMed ID: 2159198
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of neoplastic cell growth by quiescent cells is mediated by serum concentration and cAMP phosphodiesterase inhibitors.
Bertram JS; Bertram BB; Janik P
J Cell Biochem; 1982; 18(4):515-38. PubMed ID: 6282911
[No Abstract] [Full Text] [Related]
15. [Purification of cyclic nucleotide phosphodiesterase from the external segments of retinal rods; conjugation of the enzyme with an inhibitor].
Furaev VV; Dumler IL; Kazimirskiĭ AN; Etingof RN
Dokl Akad Nauk SSSR; 1978; 243(1):247-50. PubMed ID: 214282
[No Abstract] [Full Text] [Related]
16. [Inhibition of cyclic nucleotide phosphodiesterase from the rod outer segments of the frog retina by 3-hydroxypyridine].
Polianskiĭ NB; Smirnov LD; Shvedova AA; Kagan VE
Nauchnye Doki Vyss Shkoly Biol Nauki; 1984; (1):27-31. PubMed ID: 6199045
[TBL] [Abstract][Full Text] [Related]
17. Platelet aggregation and cyclic nucleotide phosphodiesterase activity in arteriosclerotic patients.
Yamazaki H; Motomiya T; Mashimo N; Asano T; Hidaka H
Thromb Haemost; 1978 Feb; 39(1):158-66. PubMed ID: 205971
[TBL] [Abstract][Full Text] [Related]
18. [Action of cyclic nucleotide phosphodiesterase inhibitors on the acetylcholine potential].
Kafengauz BIu; Poskonova MA
Biull Eksp Biol Med; 1985 May; 99(5):522-4. PubMed ID: 2408691
[TBL] [Abstract][Full Text] [Related]
19. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells.
Nishio Y; Kashiwagi A; Takahara N; Hidaka H; Kikkawa R
Horm Metab Res; 1997 Oct; 29(10):491-5. PubMed ID: 9405974
[TBL] [Abstract][Full Text] [Related]
20. Comparative studies on cyclic nucleotide phosphodiesterases and inhibitors in experimental models of hypertension, congestive heart failure, and allergic asthma.
Silver PJ; Gordon RJ; Buchholz RA; Dundore RL; Ferguson EW; Harris AL; Pagani ED
Adv Second Messenger Phosphoprotein Res; 1992; 25():341-51. PubMed ID: 1313266
[No Abstract] [Full Text] [Related]
[Next] [New Search]
